XML 38 R30.htm IDEA: XBRL DOCUMENT

Revenue from Contracts with Customers (Tables)

9 Months Ended

Sep. 30, 2025

Revenue from Contract with Customer [Abstract]

The following table summarizes revenue by source as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2025		2024		2025		2024
Major Products /Service Lines
Product revenue, net(1)	$	376,687	$	374,601	$	1,118,152	$	1,136,670
License and royalty revenues		7,327		4,133		16,671		6,130
Total revenues	$	384,014	$	378,734	$	1,134,823	$	1,142,800

(1)

The Company’s product revenue includes PYLARIFY, DEFINITY, Neuraceq and TechneLite among other products. This category represents the delivery of physical goods. The Company applies the same revenue recognition policies and judgments for all its principal products.

Revenue by product category on a net basis is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2025		2024		2025		2024
PYLARIFY	$	240,616	$	259,756	$	748,912	$	791,881
Other radiopharmaceutical oncology		—		—		—		384
Total radiopharmaceutical oncology		240,616		259,756		748,912		792,265
DEFINITY		81,785		76,965		244,935		231,629
Neuraceq		20,442		—		20,442		—
TechneLite		21,127		20,480		65,820		70,380
Other precision diagnostics		6,339		6,282		18,672		18,039
Total precision diagnostics		129,693		103,727		349,869		320,048
Strategic partnerships and other revenue		13,705		15,251		36,042		30,487
Total revenues	$	384,014	$	378,734	$	1,134,823	$	1,142,800